Invitrogen Corporation and Fred Hutchinson Cancer Research Center Team on Cancer Screening; Collaboration Will Use Proteomics Technologies to Focus on Early Cancer Diagnostics.CARLSBAD, Calif. & SEATTLE -- Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, and the Fred Hutchinson
n. The complete set of proteins that are produced by the genes of an organism. proteome the entire complement of proteins produced by a cell. and proteomics-based approaches in combination with investigations by the lab of Sam Hanash, M.D., Ph.D., at the Hutchinson Center. Invitrogen will utilize a variety of its proteomics technologies including its flagship ProtoArray(TM) protein microarrays and extensive protein and antibody collections. Invitrogen will also be able to license technologies produced as a result of the collaboration. Other terms of the collaboration were not disclosed. "We are honored to be working alongside pre-eminent scientists such as Dr. Hanash," said Invitrogen Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Gregory T. Lucier. "At Invitrogen we have developed and applied a comprehensive biotechnology platform to the challenge of accelerating drug discovery and disease research. This collaboration is another important step in our efforts to support patient-specific research." Earlier detection of cancer allows for potentially higher cure rates. The collaboration is aimed at producing enabling, industry-changing technology that will change the way diseases are diagnosed and treated. Additionally, technology developed from the partnership has the potential to greatly accelerate proteomics-based approaches for all biomedical research Biomedical research (or experimental medicine), in general simply known as medical research, is the basic research or applied research conducted to aid the body of knowledge in the field of medicine. -- one of the most crucial areas of study today. "The Fred Hutchinson Cancer Research Center is focused on preventing, diagnosing and treating cancer and other debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction disease," explained Hanash. "We are excited to work with an organization like Invitrogen to re-think cancer research. We believe this collaboration can push the boundaries of current cancer detection." Invitrogen's proteomics capabilities span a broad range of applications including protein expression, separation, characterization and target screening. The collaborative effort is highlighted by Invitrogen's ProtoArray -- a functional microarray used to measure protein interactions that could prove key to better therapeutic monitoring, and cures with far fewer drug side-effects. Currently, the ProtoArray contains more than 5,000 unique human proteins focused on key drug target families. Invitrogen has continued development of the array content with an eventual goal of capturing every significant human protein on the chips. In 2004 Invitrogen announced a partnership with Mayo Clinic Mayo Clinic: see Mayo, Charles Horace. Mayo Clinic voluntary association of more than 500 physicians in Rochester, Minnesota. [Am. Hist.: EB, 11: 723] See : Medicine around the discovery of unique cancer biomarkers using its drug discovery technology portfolio. Together these collaborations demonstrate a broad approach to oncology research utilizing different tools to solve unique challenges at each organization. "We believe that as our understanding of disease at a molecular level advances, early screening systems will play an important role in optimizing therapy," concluded Lucier. "We are hopeful screening technologies from our partnership with the Hutchinson Center will allow physicians in the future to quickly diagnose disease and determine treatment options for patients before they even know they are sick." About Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams interdisciplinary team, n a group that consists of specialists from several fields combining skills and resources to present guidance and information. of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome and other diseases. Our researchers, including three Nobel laureates Winners of the Nobel Prize are scientists, writers and peacemakers who have been awarded in their field of endeavour, and who are known collectively as either Nobel laureates or Nobel Prize winners. , bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit www.fhcrc.org. About Invitrogen Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics Noun 1. functional genomics - the branch of genomics that determines the biological function of the genes and their products genomics - the branch of genetics that studies organisms in terms of their genomes (their full DNA sequences) , proteomics, bioinformatics and cell biology Cell biology The study of the activities, functions, properties, and structures of cells. Cells were discovered in the middle of the seventeenth century after the microscope was invented. -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California Carlsbad is a coastal resort-town in northern San Diego County, California. According to the state Department of Finance, the city had a total population of 90,271 in 2003. , and conducts business in more than 70 countries around the world. The company globally employs approximately 4,500 scientists and other professionals and had revenues of more than $1 billion in 2004. For more information, visit www.invitrogen.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement Certain statements contained in this press release are considered "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to: 1) Invitrogen will utilize its expertise with the human proteome and proteomics-based approaches in combination with investigations by the lab of Dr. Hanash; 2) Invitrogen will utilize a variety of proteomics technologies including ProtoArray, protein and antibody collections; 3) Invitrogen will license technologies produced as a result of the collaboration; 4) The collaboration is aimed at producing enabling, industry-changing technology that will change the way diseases are diagnosed and treated; 5) The partnership can push the boundaries of current cancer detection. Potential risks and uncertainties include, but are not limited to, the risks: a) Invitrogen may expand or contract the specific technologies involved in the partnership; b) Invitrogen may choose not to license technologies derived from the collaboration; and c) the collaboration may have no significant impact on current cancer detection technologies, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion